Astellas Pharma Incorporated operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Astellas Pharma Incorporated with three other
companies in this sector in Japan:
Daiichi Sankyo Company Limited
sales of 986.45 billion Japanese Yen [US$8.54 billion]
of which 94%
was prescription drugs),
Eisai Company Limited
(547.92 billion Japanese Yen [US$4.75 billion]
of which 49%
was Pharmaceutical Business -Japan), and
Takeda Pharmaceutical Company Limited
(1.81 trillion Japanese Yen [US$15.65 billion]
of which 91%
was Pharmaceutical Business).
Astellas Pharma Incorporated reported sales of ¥1.37 trillion (US$11.89 billion)
March of 2016.
increase of 10.1%
versus 2015, when the company's sales were ¥1.25 trillion.
Sales at Astellas Pharma Incorporated have increased during each of the previous five years
(and since 2011, sales have increased a total of 44%).
Sales of Xtandi saw an increase
that was more than double the company's growth rate: sales were up
83.7% in 2016, from
¥137.19 billion to ¥252.08 billion.